Post-Earnings Briefing - Endo International

LONDON, March 30, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Investor-Edge.com has issued free post-earnings review on Endo International PLC (NASDAQ: ENDP). On March 02, 2015, the company reported its financial results for Q4 FY14 and full-year FY14 (period ended December 31, 2014). Click on http://get.Investor-Edge.com/pdf/?c=Endo%20Intl.&d=30-Mar-2015&s=ENDP to read our free earnings review on Endo International plc (Endo). During Q4 FY14 and full-year FY14, the company's total revenues increased 37% Y-o-Y and 10%, respectively. Moreover, Non-GAAP net income attributable to Endo surged 49% in Q4 FY14 and 18% Y-o-Y in FY14. President and CEO of Endo, Rajiv De Silva, stated that the company is proud of the progress it has made in rebuilding its business in FY14. Our free coverage report can be accessed at:

http://get.Investor-Edge.com/pdf/?c=Endo%20Intl.&d=30-Mar-2015&s=ENDP

Earnings Overview 

During Q4 FY14, Endo's total revenues increased to $799.96 million from $584.95 million in Q4 FY13. The company's Q4 FY14 total revenues exceeded Bloomberg analysts' forecasts of $781.67 million. In Q4 FY14, Endo's total U.S. Branded Pharmaceuticals net revenue fell 3% Y-o-Y to $245.79 million. However, the company's total U.S. Generic Pharmaceuticals and total Devices net revenue increased 70% Y-o-Y and 4% Y-o-Y, respectively, to $337.35 million and $137.08 million in Q4 FY14. Additionally, Endo reported total International Pharmaceuticals net revenue of $79.73 million in Q4 FY14. Free research on ENDP can be downloaded in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Endo%20Intl.&d=30-Mar-2015&s=ENDP

For Q4 FY14, GAAP net loss attributable to Endo narrowed down to $53.48 million, or $0.35 per diluted share, from GAAP net loss attributable to Endo of $775.91 million, or $6.74 per diluted share, in Q4 FY13. Analysts from Bloomberg had expected Q4 FY14 GAAP net income attributable to Endo of $109.93 million, or $0.69 per diluted share. Moreover, Q4 FY14 Non-GAAP net income attributable to Endo improved to $184.88 million, or $1.16 per diluted share, from $123.70 million, or $0.96 per diluted share, in Q4 FY13.

In FY14, Endo reported total revenues of $2.88 billion compared to $2.62 billion in FY13. The company's FY14 total revenues slightly exceeded Bloomberg analysts' forecasts of $2.86 billion. GAAP net loss attributable to Endo stood at $721.32 million, or $4.91 per diluted share, in FY14 compared to GAAP net loss attributable to Endo of $685.34 million, or $6.05 per diluted share, in FY13. Analysts from Bloomberg had expected GAAP net loss attributable to Endo of $558.33 million, or $3.89 per diluted share, in FY14.

On January 29, 2015 Endo announced that it has completed the acquisition of Auxilium Pharmaceuticals Inc., and the combined company is expected to provide an expanded platform to boost the evolution and growth of Endo's U.S. Branded Pharmaceuticals business. Consequently, following the acquisition, the company's portfolio has a broader offering of urology and orthopedic products. Mr. De Silva said that the acquisition more broadly supports Endo's objective to deliver high-single to low-double digit organic growth for revenues over the mid-term.

On March 02, 2015, Endo announced a definitive agreement with Boston Scientific to sell its American Medical Systems' Men's Health and Prostate Health businesses (AMS) for up to $1.65 billion, with $1.6 billion in upfront cash. Sign up and read the free analyst's notes on ENDP at:

http://get.Investor-Edge.com/pdf/?c=Endo%20Intl.&d=30-Mar-2015&s=ENDP

For FY15, Endo expects revenues, excluding AMS, to range between $2.90 billion and $3.00 billion. It also anticipates FY15 GAAP diluted earnings per share from continuing operations and adjusted diluted earnings per share from continuing operations, excluding AMS, in the range of $2.73 to $2.93 and $4.35 to $4.55, respectively.

Stock Performance  

On the day of the earnings release, March 02, 2015, Endo's stock gained 2.01% to end the session at $87.32. Since then, the stock has moved both ways with gains outperforming losses. On the last close, Friday, March 27, 2015, the company's shares finished 2.54% higher at $90.04, and vacillated between $87.46 and $90.51. A total of 2.56 million shares were traded which was below their three months average volume of 3.13 million shares. Over the last one month and over the previous three months, the company's shares have gained 5.19% and 23.07%, respectively. Additionally, the stock surged 34.67% in the past one year. Visit Investor-Edge and access the latest research on ENDP at:

http://get.Investor-Edge.com/pdf/?c=Endo%20Intl.&d=30-Mar-2015&s=ENDP

Sneak Peek to Corporate Insider Trading 

In the last one month, there were 10 corporate insider transactions done by five individuals. Between February 27, 2015 and March 11, 2015, a total of 82,471 shares were purchased at an average price of $25.89 per share and for a total value of $2.14 million. During the same period, a total of 90,509 shares, worth $7.90 million, were sold at an average price of $87.25 per share. The following are some of the abovementioned transactions: Caroline B. Manogue, Executive Vice President, Chief Legal Officer at Endo, bought 42,033 shares at an average price of $19.93 per share and sold 43,042 shares at an average price of $87.72 per share; Camille Farhat, President of AMS at Endo, purchased 40,438 shares at an average price of $32.09 per share and disposed 40,790 shares at an average price of $87.01 per share; on March 04, 2015, Brian Lortie, President of U.S. Branded Pharmaceuticals at Endo, sold 5,800 shares at an average price of $85.35 per share. Complimentary in-depth research on ENDP is available at:

http://get.Investor-Edge.com/pdf/?c=Endo%20Intl.&d=30-Mar-2015&s=ENDP

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge